Key result
Usual care control arms in randomized trials enhance generalizability but introduce variability that may reduce observed treatment differences and require larger sample sizes.
Why the study?
Selection of the control arm is critical in randomized trials, and this review aims to describe the use, advantages, and limitations of usual care arms.
This review highlights that while usual care control arms in randomized trials enhance generalizability, they introduce variability that may require larger sample sizes or lead to negative results.
Usual care controls risk diluting effects or requiring larger trials; leaves open optimal control-arm designs for future RCTs.
PURPOSE OF REVIEW: The aim of this review is to describe the use of usual care arms in randomized trials. RECENT FINDINGS: Randomization of patients to an experimental or a control arm remains paramount for the estimation of average causal effects. Selection of the control arm is as important as the definition of the intervention, and it might include a placebo control, specific standards of care, protocolized usual care, or unrestricted clinical practice. Usual care control arms may enhance generalizability, clinician acceptability of the protocol, patient recruitment, and ensure community equipoise, while at the same time introducing significant variability in the care delivered in the control group. This effect may reduce the difference in treatments delivered between the two groups and lead to a negative result or the requirement for a larger sample size. Moreover, usual care control groups can be subject to changes in clinician behavior induced by the trial itself, or by secular trends in time. SUMMARY: Usual care control arms may enhance generalizability while introducing significant limitations. Potential solutions include the use of pretrial surveys to evaluate the extent to which a protocolized control arm reflects the current standard of care and the implementation of adaptive trials.
No takes yet. Share an insight, caveat, or question.
Angriman et al. (2019) reported a review. Usual care arms was evaluated. Usual care control arms in randomized trials enhance generalizability but introduce variability that may reduce observed treatment differences and require larger sample sizes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: